Abstract:Deubiquitinating enzymes (DUBs) appear to be a new class of regulators of cardiac homeostasis and disease. However, DUB-mediated signaling in the heart is not well understood. Herein we report a novel mechanism by which cylindromatosis (CYLD), a DUB mediates cardiac pathological remodeling and dysfunction. Cardiomyocyte-restricted (CR) overexpression of CYLD (CR-CYLD) did not cause gross health issues and hardly affected cardiac function up to age of one year in both female and male mice at physiological conditions. However, CR-CYLD overexpression exacerbated pressure overload (PO)-induced cardiac dysfunction associated with suppressed cardiac hypertrophy and increased myocardial apoptosis in mice independent of the gender. At the molecular level, CR-CYLD overexpression enhanced PO-induced increases in poly-ubiquitinated proteins marked by lysine (K)48-linked ubiquitin chains and autophagic vacuoles containing undegraded contents while suppressing autophagic flux. Augmentation of cardiac autophagy via CR-ATG7 overexpression protected against PO-induced cardiac pathological remodeling and dysfunction in both female and male mice. Intriguingly, CR-CYLD overexpression switched the CR-ATG7 overexpression-dependent cardiac protection into myocardial damage and dysfunction associated with increased accumulation of autophagic vacuoles containing undegraded contents in the heart. Genetic manipulation of Cyld in combination with pharmacological modulation of autophagic functional status revealed that CYLD suppressed autolysosomal degradation and promoted cell death in cardiomyocytes. In addition, Cyld gene gain- and/or loss-of-function approaches in vitro and in vivo demonstrated that CYLD mediated cardiomyocyte death associated with impaired reactivation of mechanistic target of rapamycin complex 1 (mTORC1) and upregulated Ras genes from rat brain 7 (Rab7), two key components for autolysosomal degradation. These results demonstrate that CYLD serves as a novel mediator of cardiac pathological remodeling and dysfunction by suppressing autolysosome efflux in cardiomyocytes. Mechanistically, it is most likely that CYLD suppresses autolysosome efflux via impairing mTORC1 reactivation and interrupting Rab7 release from autolysosomes in cardiomyocytes.

Deubiquitinating Enzyme CYLD Negatively Regulates the Ubiquitin-Dependent Kinase Tak1 and Prevents Abnormal T Cell Responses

Regulation of the Deubiquitinating Enzyme CYLD by IκB Kinase Gamma-Dependent Phosphorylation

Regulation of Natural Killer T-cell Development by Deubiquitinase CYLD

Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination

Regulation Of I Kappa B Kinase-Related Kinases And Antiviral Responses By Tumor Suppressor Cyld

Deubiquitinase CYLD Controls the Plasticity of T-reg Cells by Regulation of Scinderin Expression

The Deubiquitinase CYLD Controls Protective Immunity Against Helminth Infection by Regulation of Treg Cell Plasticity.

Cylindromatosis (CYLD), a Deubiquitinase, Attenuates Inflammatory Signaling Pathways by Activating Toll-Like Receptor 3 in Human Mesangial Cells

A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells.

Tumor suppressor CYLD regulates JNK-induced cell death in Drosophila.

Constitutive expression of the deubiquitinating enzyme CYLD does not affect microglia phenotype or function in homeostasis and neuroinflammation

An emerging role of deubiquitinating enzyme cylindromatosis (CYLD) in the tubulointerstitial inflammation of IgA nephropathy.

Regulation of Antiviral Innate Immunity by Deubiquitinase Cyld

Cyld Deubiquitinates Rip1 In The Tnf Alpha-Induced Necrosome To Facilitate Kinase Activation And Programmed Necrosis

Mutual Regulation Between Deubiquitinase CYLD and Retroviral Oncoprotein Tax

CYLD exaggerates pressure overload-induced cardiomyopathy via suppressing autolysosome efflux in cardiomyocytes

Cyld restrains the hyperactivation of synovial fibroblasts in inflammatory arthritis by regulating the TAK1/IKK2 signaling axis

The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response

CALML6 Controls TAK1 Ubiquitination and Confers Protection against Acute Inflammation

Usp16-Mediated Deubiquitination Of Calcineurin A Controls Peripheral T Cell Maintenance

CYLD Negatively Regulates Transforming Growth Factor-Β-signalling Via Deubiquitinating Akt